Frederik Peissert
Overview
Explore the profile of Frederik Peissert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elsayed A, Pluss L, Nideroest L, Rotta G, Thoma M, Zangger N, et al.
Mol Cancer Ther
. 2024 Apr;
23(7):1010-1020.
PMID: 38638035
Metastatic colorectal cancer remains a leading cause of cancer-related deaths, with a 5-year survival rate of only 15%. T cell-engaging bispecific antibodies (TCBs) represent a class of biopharmaceuticals that redirect...
2.
Peissert F, Pedotti M, Corbellari R, Simonelli L, De Gasparo R, Tamagnini E, et al.
Glob Chall
. 2023 Oct;
7(10):2300088.
PMID: 37829677
Neutralizing monoclonal antibodies have achieved great efficacy and safety for the treatment of numerous infectious diseases. However, their neutralization potency is often rapidly lost when the target antigen mutates. Instead...
3.
Elsayed A, Pellegrino C, Pluss L, Peissert F, Benz R, Ulrich F, et al.
MAbs
. 2023 Jun;
15(1):2220839.
PMID: 37288872
Antibody-based therapeutics represent an important class of biopharmaceuticals in cancer immunotherapy. CD3 bispecific T-cell engagers activate cytotoxic T-cells and have shown remarkable clinical outcomes against several hematological malignancies. The absence...
4.
Pluss L, Peissert F, Elsayed A, Rotta G, Romer J, Dakhel Plaza S, et al.
MAbs
. 2023 May;
15(1):2217964.
PMID: 37243574
There are no effective treatment options for most patients with metastatic colorectal cancer (mCRC). mCRC remains a leading cause of tumor-related death, with a five-year survival rate of only 15%,...
5.
Peissert F, Pluss L, Giudice A, Ongaro T, Villa A, Elsayed A, et al.
Protein Sci
. 2022 Nov;
31(12):e4486.
PMID: 36317676
Programmed cell death protein 1 (PD-1) is an immunoregulatory target which is recognized by different monoclonal antibodies, approved for the therapy of multiple types of cancer. Different anti-PD-1 antibodies display...
6.
Nadal L, Peissert F, Elsayed A, Weiss T, Look T, Weller M, et al.
J Immunother Cancer
. 2022 Sep;
10(9).
PMID: 36104101
Background: In this study, we describe the generation of a fully human monoclonal antibody (named '7NP2') targeting human fibroblast activation protein (FAP), an antigen expressed in the microenvironment of different...
7.
Peissert F, Graf H, Muller B, Abruzzese T, Abele H, Aicher W
Stem Cells Int
. 2021 Apr;
2021:6662201.
PMID: 33868409
Mesenchymal stromal cells (MSCs) have been successfully employed in clinical applications. In most studies, autologous MSCs from the bone marrow (bmMSCs) were used, and others employed autologous adipose tissue-derived stromal...